[Blood-brain barrier part III: therapeutic approaches to cross the blood-brain barrier and target the brain]
- PMID: 19699499
- DOI: 10.1016/j.neurol.2009.06.005
[Blood-brain barrier part III: therapeutic approaches to cross the blood-brain barrier and target the brain]
Abstract
Over the last few years, the blood-brain barrier has come to be considered as the main limitation for the treatment of neurological diseases caused by inflammatory, tumor or neurodegenerative disorders. In the blood-brain barrier, the close intercellular contact between cerebral endothelial cells due to tight junctions prevents the passive diffusion of hydrophilic components from the bloodstream into the brain. Several specific transport systems (via transporters expressed on cerebral endothelial cells) are implicated in the delivery of nutriments, ions and vitamins to the brain; other transporters expressed on cerebral endothelial cells extrude endogenous substances or xenobiotics, which have crossed the cerebral endothelium, out of the brain and into the bloodstream. Recently, several strategies have been proposed to target the brain, (i) by by-passing the blood-brain barrier by central drug administration, (ii) by increasing permeability of the blood-brain barrier, (iii) by modulating the expression and/or the activity of efflux transporters, (iv) by using the physiological receptor-dependent blood-brain barrier transport, and (v) by creating new viral or chemical vectors to cross the blood-brain barrier. This review focuses on the illustration of these different approaches.
Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier.Curr Drug Metab. 2013 Jul;14(6):625-40. doi: 10.2174/1389200211314060001. Curr Drug Metab. 2013. PMID: 23869808 Review.
-
In Vitro and Ex Vivo Model Systems to Measure ABC Transporter Activity at the Blood-Brain Barrier.Curr Pharm Des. 2016;22(38):5768-5773. doi: 10.2174/1381612822666160810145536. Curr Pharm Des. 2016. PMID: 27514708 Review.
-
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.Prog Neurobiol. 2005 May;76(1):22-76. doi: 10.1016/j.pneurobio.2005.04.006. Prog Neurobiol. 2005. PMID: 16011870 Review.
-
The role of membrane transporters in drug delivery to brain tumors.Cancer Lett. 2007 Aug 28;254(1):11-29. doi: 10.1016/j.canlet.2006.12.023. Epub 2007 Jan 31. Cancer Lett. 2007. PMID: 17275180 Review.
-
Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis.Inflammopharmacology. 2018 Jun;26(3):675-684. doi: 10.1007/s10787-018-0468-y. Epub 2018 Mar 26. Inflammopharmacology. 2018. PMID: 29582240 Review.
Cited by
-
Predicting blood-brain barrier permeability of molecules with a large language model and machine learning.Sci Rep. 2024 Jul 9;14(1):15844. doi: 10.1038/s41598-024-66897-y. Sci Rep. 2024. PMID: 38982309 Free PMC article.
-
Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.Adv Pharm Bull. 2016 Sep;6(3):319-335. doi: 10.15171/apb.2016.044. Epub 2016 Sep 25. Adv Pharm Bull. 2016. PMID: 27766216 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical